GEO for Biotech: How Scientific Publications Drive AI Citation Visibility

TL;DR: For biotech, AI citation visibility runs through the scientific literature itself, not a marketing page. PubMed indexing, preprint servers, entity markup like ORCID and ScholarlyArticle schema, and trade-press amplification all shape whether ChatGPT, Perplexity, and Gemini cite a company’s science accurately, or cite it at all.

ChatGPT reached 1,000 mentions in PubMed-indexed papers within nine months of its release. Google took fourteen years to hit the same citation milestone. That gap says something specific about biotech: the channel through which AI models learn about a company’s science has already shifted, and it shifted faster here than almost anywhere else.

Specialized biomedical language models make the point even sharper. BioGPT and BioMedLM are trained directly on 15 to 16 million PubMed abstracts and articles. For a biotech, the published paper is no longer just the end of the distribution chain for its science. It’s the beginning of a new one, feeding directly into the models that investors, researchers, and business-development partners now ask about your pipeline.

Where to Jump In

• Why GEO Is Different for Biotech
• How AI Engines Actually Find and Cite Scientific Publications
• The Levers That Turn a Paper Into an AI Citation
• How to Measure Your AI Citation Visibility
• FAQ

Why GEO Is Different for Biotech

GEO for biotech is the practice of shaping how AI engines discover, summarize, and cite a company’s scientific publications, trial data, and pipeline information, for an audience of investors, researchers, and business-development partners rather than consumers. It follows the same Visibility, Citability, Retrievability framework as any GEO program, but the inputs are different: the raw material is peer-reviewed literature and trial registries, not blog posts.

That distinction is what makes AI citation visibility for biotech a different problem than for most industries. AI Overviews now appear on roughly 51 percent of healthcare searches, a shift that has already cut organic traffic to preprint servers. Researchers and investors increasingly read an AI-generated summary of a finding rather than the paper itself. Whoever shapes that summary effectively controls how the science gets understood before anyone clicks through, if they click through at all.

Takeaway: for biotech, the paper is the content strategy. Everything else, including this article’s own recommendations, is about making sure AI engines find it, trust it, and represent it accurately.

How AI Engines Actually Find and Cite Scientific Publications

Modern AI search tools query multiple biomedical databases in parallel, including PubMed, ClinicalTrials.gov, and preprint servers like bioRxiv and medRxiv, then synthesize an answer from what they retrieve. Three structural facts shape what gets pulled into that answer.

First, indexing timing matters. bioRxiv and medRxiv publish findings six to twelve months ahead of the peer-reviewed version in fast-moving fields. NIH’s PubMed preprint-citation pilot, running since 2020, means a preprint can already be citable infrastructure before formal peer review completes.

Second, general-purpose engines like Gemini apply an E-E-A-T lens even to scientific content: they favor mainstream, corroborated claims and can be cautious with a single, unreplicated finding, however strong. A result that only exists in one paper reads as riskier to cite than one echoed across several independent sources.

Third, specialized biomedical models trained on the PubMed corpus itself, like BioGPT and BioMedLM, sit alongside general engines in this landscape. A finding that’s well represented in PubMed’s structured abstracts has a retrieval advantage that a press release alone doesn’t confer.

Takeaway: getting cited starts with getting indexed correctly, and being corroborated, not just published once.

The Levers That Turn a Paper Into an AI Citation

A handful of concrete levers drive AI citation visibility more than anything else, separating a paper that gets cited accurately from one an AI engine ignores or garbles.

• Entity markup on the paper’s landing page. Linking an author’s ORCID identifier to an Organization schema for the lab or company is one of the highest-value additions available; it removes ambiguity about who did the work and where it came from.
• ScholarlyArticle schema. Structured markup that clearly identifies a page as a scholarly article reduces the ambiguity AI systems have to resolve before citing it, and functions as a trust signal rather than a ranking trick.
• FAQPage schema on supporting pages. Independent 2025 research found a median 22 percent lift in AI citation rates on pages that added genuine FAQ schema, with the largest gains on Perplexity and Bing Copilot.
• Statistics paired with named sources. Citing a named, checkable source alongside a statistic produced a roughly 30.6 percent lift in one study, and pages that cite authoritative sources see about a 40 percent gain in AI visibility overall, a pattern a Princeton and Georgia Tech GEO study first documented.
• Trade-press amplification. Coverage in outlets like STAT News, Endpoints News, and FierceBiotech translates a primary finding into a secondary, corroborating source. Gemini’s E-E-A-T lens rewards that, and it gives ChatGPT and Perplexity another independent citation to draw from.

Takeaway: none of these levers replace real science. They remove the friction between a real finding and an AI engine’s ability to find, verify, and cite it correctly.

How Pepper Does It

Pepper’s Citation Analysis names the exact domains and sources an engine is pulling from for a given query. For a biotech, that means seeing directly whether it’s citing your primary paper, a trade-press writeup of it, a competitor’s, or nothing at all. Agents & Sheets can then help a science or communications team turn a finding into the schema-marked, FAQ-structured supporting pages described above. Human review stays built into that workflow before anything about a company’s science goes live.

Pepper doesn’t yet have a published biotech case study to point to here, and it’s worth saying that plainly rather than stretching a result from a different sector to fit.

How to Measure Your AI Citation Visibility

Measuring AI citation visibility takes more than checking whether your name comes up once. Track it on a cadence:

• Track Citation Rate, the share of relevant prompts where your work gets cited at all, as a baseline before changing anything.
• Watch Share of Answer over time rather than a single snapshot; a single indexed paper can take months to compound into consistent citation.
• Manually test three real investor or researcher questions about your pipeline in ChatGPT, Perplexity, and Gemini each quarter, and check the cited sources against what you’d want cited.
• Watch for hallucinated claims specifically: a wrong trial phase or misstated endpoint is a different problem than low visibility, and it needs a faster response.

FAQ

How do AI engines like ChatGPT find scientific publications?

They retrieve from indexed sources including PubMed, ClinicalTrials.gov, and preprint servers like bioRxiv and medRxiv, then synthesize an answer. Specialized biomedical models such as BioGPT are trained directly on PubMed’s corpus.

Do preprints affect AI citation visibility before peer review?

Yes. bioRxiv and medRxiv preprints often appear six to twelve months before the peer-reviewed version, and NIH’s PubMed preprint-citation pilot has included preprints in citation data since 2020.

What is the fastest way to improve AI citation visibility for a paper?

Add ScholarlyArticle and FAQPage schema, link an ORCID to an Organization entity, and secure trade-press coverage. These reduce the ambiguity AI engines have to resolve before citing a source.

Does trade press like STAT News or Endpoints News actually help AI citation?

Yes. Independent coverage acts as a corroborating source that engines like Gemini weigh favorably. A finding echoed by more than one credible outlet reads as more reliable than a single primary source alone.

Is GEO for biotech the same as GEO for pharma?

No. Pharma’s AI search challenge centers on FDA-regulated, patient-facing disease-awareness content. Biotech’s runs through investor- and researcher-facing scientific publications and pipeline data instead.

See How Pepper Can Help

The published paper used to be where a biotech’s communication work ended. Now it’s where the part that reaches investors, BD partners, and researchers actually begins, filtered through whatever an AI engine decides to say about it. If you want real AI citation visibility into what AI engines are already citing, or missing, about your science, see how Pepper’s Citation Analysis works. Or browse Pepper’s case studies to see the same approach applied in the sectors we’ve verified so far.